JP2013517254A - ハロゲン化エーテル複合体 - Google Patents
ハロゲン化エーテル複合体 Download PDFInfo
- Publication number
- JP2013517254A JP2013517254A JP2012548444A JP2012548444A JP2013517254A JP 2013517254 A JP2013517254 A JP 2013517254A JP 2012548444 A JP2012548444 A JP 2012548444A JP 2012548444 A JP2012548444 A JP 2012548444A JP 2013517254 A JP2013517254 A JP 2013517254A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- complex
- cyclodextrin
- sevoflurane
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002170 ethers Chemical class 0.000 title abstract description 5
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims abstract description 31
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims abstract description 21
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims abstract description 20
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 claims description 25
- 229960002078 sevoflurane Drugs 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 239000002131 composite material Substances 0.000 claims description 10
- 230000003444 anaesthetic effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003537 desflurane Drugs 0.000 claims description 2
- DPYMFVXJLLWWEU-UHFFFAOYSA-N desflurane Chemical compound FC(F)OC(F)C(F)(F)F DPYMFVXJLLWWEU-UHFFFAOYSA-N 0.000 claims description 2
- 229960000305 enflurane Drugs 0.000 claims description 2
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 claims description 2
- 229960002725 isoflurane Drugs 0.000 claims description 2
- 229960002455 methoxyflurane Drugs 0.000 claims description 2
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 5
- 238000001816 cooling Methods 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 description 15
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 8
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 5
- 229940097362 cyclodextrins Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012482 calibration solution Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003983 inhalation anesthetic agent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Polymers & Plastics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
a) α−シクロデキストリン水溶液を調製し、
b) フルランを水溶液に加え、
c) 沈殿した複合体を回収する
工程を含む、本発明の複合体を製造する方法を提供する。
1. 材料
・精製水(Millipore Q品質の水)
・α−シクロデキストリン
・β−シクロデキストリン
・2−ヒドロキシプロピル−β−シクロデキストリン
・メチル−β−シクロデキストリン(RAMEB)
・セボフルラン
全てのシクロデキストリン類を、Cyclo Lab Cyclodextrin Research & Development Laboratory Ltd., Hungaryから購入した。セボフルランをAbbott GmbH, Wiesbadenから購入した。
複合体のセボフルラン含量を、ガスクロマトグラフィーによって測定した。ガスクロマトグラフィー条件は、下記の通りであった:
ガスクロマトグラフ:Shimadzu GC-17A
検出器:水素炎イオン化型検出器(FID)
インジェクター:Shimadzu AoC-5000 オートインジェクター
ソフトウェア:Shimadzu Class-VP 7.4 version
ガス:
キャリア:ヘリウム(99.999%)
さらなるガス:窒素(99.999%)
合成空気(99.999%)
水素(Whatman hydrogen generator)
カラム:Rtx624 (30m×0.32mm×1.8mm) (Restek)
温度プログラム:
検出器温度:220℃
スプリット比 100:1
流速:30cm/秒
インジェクションプログラムは下記の通りであった:60℃で10分間インキュベーションした後、250μlの体積の蒸気サンプルを、70℃で、ガスクロマトグラフに注入した。
比較溶液:250μlのDMFを含む1mlの蒸留水をバイアルに入れる
較正溶液:ストック溶液として、2mlの硝子瓶に100mgのセボフルランを秤量し、DMFをマークまで入れる
種々の量のストック溶液(20、65、110、155および200μl)をそれぞれDMFで200μlにして、1mlの蒸留水と共にヘッドスペースバイアル(19.5ml)に入れる。
サンプル溶液:50mgのサンプル溶液を、1mlの蒸留水および200μlのDMFと共に、ヘッドスペースバイアル(19.5ml)に入れる。さらに、1mlの母液(沈殿した複合体を取った後のシクロデキストリンとセボフルランの複合体の上清から調製)を、200μlのDMFと共に、ヘッドスペースバイアル(19.5ml)に入れる。
この実施例は、セボフルランのα−シクロデキストリン(α−CD)複合体の製造を記載する。
丸底フラスコに、室温で、継続的に撹拌しながら、45.25g(0.0465mol)のα−CDを500mlの水に溶解した。α−CDが完全に溶解した後、6ml(0.0465mol)のセボフルランを、室温で溶液に加えた。白色の沈殿が生じ、それを氷水で5〜10℃に冷却した。混合物をこの温度で4時間撹拌し、フラスコを冷蔵庫中で一夜置いた。次に、沈殿したセボフルラン/α−CD複合体の結晶を濾過して取り、減圧下、五酸化リンで乾燥させた。
この実施例は、複合体形成に対する適当なシクロデキストリンの選択の影響を示す。比較のために、β−シクロデキストリン(β−CD)、ヒドロキシプロピル−β−シクロデキストリン(HP−β−CD)およびRAMEBを用いた。これらの比較例は、本発明に含まれない。
1mlの4種のシクロデキストリン類の水溶液をそれぞれ調製した。この水溶液におけるシクロデキストリン類の濃度は、下記の通りであった:
α−CD:10重量%
β−CD:2重量%
HP−β−CD:10重量%
RAMEB:10重量%
HP−β−CDおよびRAMEBの場合は、均一な溶液が得られ;複合体は沈殿しなかった。
α−CDおよびβ−CDでは、白色の沈殿物が形成した。
沈殿した複合体のセボフルラン含量をガスクロマトグラフィーによって測定した。結果を下記の表に示す。
Claims (11)
- α−シクロデキストリンおよびフルランから形成された複合体であって、複合体の総重量に対して少なくとも3重量%のフルラン含量を特徴とする、複合体。
- フルラン含量が、少なくとも5重量%、好ましくは少なくとも7重量%、より好ましくは少なくとも8重量%、より好ましくは8〜12重量%である、請求項1に記載された複合体。
- フルランが、セボフルラン、エンフルラン、イソフルラン、デスフルランおよびメトキシフルランからなる群から選択されることを特徴とする、請求項1または2に記載された複合体。
- 5〜15重量%、好ましくは7〜13重量%の水含量を有することを特徴とする、請求項1〜3の何れか1項に記載された複合体。
- 医薬として使用するための、請求項1〜4の何れか1項に記載された複合体。
- 請求項1〜4の何れか1項に記載された複合体を含むことを特徴とする、経口および/または静脈内投与用に製剤化された麻酔剤。
- a) α−シクロデキストリンの水溶液を調製し、
b) フルランを水溶液に加え、
c) 沈殿した複合体を回収する
工程によって特徴付けられる、請求項1〜4の何れか1項に記載された複合体を製造する方法。 - 工程a)で調製される水溶液中のα−シクロデキストリンの濃度が、5〜30重量%、好ましくは5〜20重量%、より好ましくは5〜15重量%であることを特徴とする、請求項7に記載された方法。
- 工程b)で、フルラン対α−シクロデキストリンが1:0.5〜1:2、好ましくは1:0.8〜1:1.2のモル比で加えられることを特徴とする、請求項7または8に記載された方法。
- 工程b)で、フルランが室温で加えられることを特徴とする、請求項7〜9の何れか1項に記載された方法。
- フルラン添加に続いて、好ましくは5と10℃の間の温度まで冷却することを特徴とする、請求項7〜10の何れか1項に記載された方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20100150786 EP2345427A1 (de) | 2010-01-14 | 2010-01-14 | Flurankomplex |
EP10150786.1 | 2010-01-14 | ||
PCT/EP2011/050428 WO2011086146A1 (de) | 2010-01-14 | 2011-01-14 | Flurankomplex |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013517254A true JP2013517254A (ja) | 2013-05-16 |
JP5752710B2 JP5752710B2 (ja) | 2015-07-22 |
Family
ID=42145043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012548444A Active JP5752710B2 (ja) | 2010-01-14 | 2011-01-14 | ハロゲン化エーテル複合体 |
Country Status (16)
Country | Link |
---|---|
US (1) | US9125953B2 (ja) |
EP (2) | EP2345427A1 (ja) |
JP (1) | JP5752710B2 (ja) |
KR (1) | KR101767283B1 (ja) |
CN (1) | CN102933235B (ja) |
CA (1) | CA2787115C (ja) |
CY (1) | CY1115967T1 (ja) |
DK (1) | DK2523691T3 (ja) |
ES (1) | ES2527010T3 (ja) |
HR (1) | HRP20141273T1 (ja) |
PL (1) | PL2523691T3 (ja) |
PT (1) | PT2523691E (ja) |
RS (1) | RS53714B1 (ja) |
SI (1) | SI2523691T1 (ja) |
SM (1) | SMT201400194B (ja) |
WO (1) | WO2011086146A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160125406A (ko) * | 2014-02-28 | 2016-10-31 | 자피오텍 게엠베하 | 플루레인 복합체의 제조 방법 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104870001B (zh) | 2012-11-15 | 2019-01-18 | 赛博尔泰克股份公司 | 用作消炎或免疫抑制有效成分的飞燕草素络合物 |
US9511047B2 (en) | 2012-12-11 | 2016-12-06 | Sapiotec Gmbh | Delphinidin for combating melanoma cells |
CN209194072U (zh) * | 2015-06-30 | 2019-08-02 | 珀金埃尔默健康科学股份有限公司 | 气相色谱系统 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009094460A2 (en) * | 2008-01-22 | 2009-07-30 | Vapogenix, Inc. | Volatile anesthetic compositions and methods of use |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3216897A (en) * | 1961-11-02 | 1965-11-09 | Air Reduction | Injectable anesthetic |
US4725442A (en) * | 1983-06-17 | 1988-02-16 | Haynes Duncan H | Microdroplets of water-insoluble drugs and injectable formulations containing same |
GB2350297A (en) * | 1999-05-27 | 2000-11-29 | Abbott Lab | Injectable halogenated anesthetic formulation in emulsion form |
CN1116031C (zh) * | 1999-08-17 | 2003-07-30 | 刘进 | 静脉注射用乳化吸入全身麻醉药及其制备方法 |
IN187686B (ja) * | 2000-06-21 | 2002-06-08 | Bharat Serums & Vaccines Ltd | |
CN1424112A (zh) * | 2002-12-17 | 2003-06-18 | 上海医药工业研究院 | 难溶性药物的水溶性包合物及其制备方法 |
US9000048B2 (en) * | 2006-11-28 | 2015-04-07 | Wisconsin Alumni Research Foundation | Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics |
-
2010
- 2010-01-14 EP EP20100150786 patent/EP2345427A1/de not_active Withdrawn
-
2011
- 2011-01-14 CA CA2787115A patent/CA2787115C/en active Active
- 2011-01-14 EP EP11700182.6A patent/EP2523691B1/de active Active
- 2011-01-14 WO PCT/EP2011/050428 patent/WO2011086146A1/de active Application Filing
- 2011-01-14 KR KR1020127021183A patent/KR101767283B1/ko active IP Right Grant
- 2011-01-14 RS RS20140702A patent/RS53714B1/en unknown
- 2011-01-14 DK DK11700182T patent/DK2523691T3/en active
- 2011-01-14 SI SI201130352T patent/SI2523691T1/sl unknown
- 2011-01-14 CN CN201180006184.7A patent/CN102933235B/zh active Active
- 2011-01-14 PT PT117001826T patent/PT2523691E/pt unknown
- 2011-01-14 US US13/522,109 patent/US9125953B2/en active Active
- 2011-01-14 JP JP2012548444A patent/JP5752710B2/ja active Active
- 2011-01-14 PL PL11700182T patent/PL2523691T3/pl unknown
- 2011-01-14 ES ES11700182.6T patent/ES2527010T3/es active Active
-
2014
- 2014-12-29 SM SM201400194T patent/SMT201400194B/xx unknown
- 2014-12-30 CY CY20141101093T patent/CY1115967T1/el unknown
- 2014-12-31 HR HRP20141273AT patent/HRP20141273T1/hr unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009094460A2 (en) * | 2008-01-22 | 2009-07-30 | Vapogenix, Inc. | Volatile anesthetic compositions and methods of use |
Non-Patent Citations (2)
Title |
---|
JPN5013003621; VIERNSTEIN H: 'INTRAVENOUS ANAESTHESIA WITH ISOFLURANE IN THE RABBIT' PHARMACEUTICAL AND PHARMACOLOGICAL LETTERS V3 N5, 19940101, P165-168 * |
JPN6014011310; Science Vol251, No.4993, 1991, p.560-561 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160125406A (ko) * | 2014-02-28 | 2016-10-31 | 자피오텍 게엠베하 | 플루레인 복합체의 제조 방법 |
JP2017506660A (ja) * | 2014-02-28 | 2017-03-09 | ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングSAPIOTEC GmbH | フルラン複合体を製造するための方法 |
KR102396557B1 (ko) | 2014-02-28 | 2022-05-10 | 자피오텍 게엠베하 | 플루레인 복합체의 제조 방법 |
Also Published As
Publication number | Publication date |
---|---|
EP2345427A1 (de) | 2011-07-20 |
SMT201400194B (it) | 2015-03-05 |
PT2523691E (pt) | 2015-01-05 |
RS53714B1 (en) | 2015-04-30 |
CN102933235A (zh) | 2013-02-13 |
HRP20141273T1 (hr) | 2015-02-27 |
EP2523691A1 (de) | 2012-11-21 |
CA2787115C (en) | 2017-10-24 |
SI2523691T1 (sl) | 2015-02-27 |
KR20120105563A (ko) | 2012-09-25 |
US9125953B2 (en) | 2015-09-08 |
DK2523691T3 (en) | 2015-01-12 |
ES2527010T3 (es) | 2015-01-19 |
CA2787115A1 (en) | 2011-07-21 |
CN102933235B (zh) | 2015-11-25 |
PL2523691T3 (pl) | 2015-03-31 |
JP5752710B2 (ja) | 2015-07-22 |
US20120296077A1 (en) | 2012-11-22 |
CY1115967T1 (el) | 2017-01-25 |
EP2523691B1 (de) | 2014-10-01 |
KR101767283B1 (ko) | 2017-08-10 |
WO2011086146A1 (de) | 2011-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1950227B1 (en) | HYDROXYPROPYL-SULFOBUTYL-ß-CYCLODEXTRIN, THE PREPARATION METHOD,THE ANALYTICAL METHOD AND THE PHARMACUTICAL APPLICATION THEREOF | |
JP5752710B2 (ja) | ハロゲン化エーテル複合体 | |
US10085949B2 (en) | Method for producing a flurane complex | |
CN107029248A (zh) | 白藜芦醇固体分散体及增加白藜芦醇在红酒中的溶解度的方法 | |
Liu et al. | Carbon Nitride‐Based siRNA Vectors with Self‐Produced O2 Effects for Targeting Combination Therapy of Liver Fibrosis via HIF‐1α‐Mediated TGF‐β1/Smad Pathway | |
CN104151451A (zh) | 一种羟丙基-β-环糊精的制备方法 | |
CA2835232C (en) | A complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof | |
KR20120047762A (ko) | 시클로덱스트린 또는 시클로덱스트린 유도체 및 할로겐화 에테르로 이루어진 1:1, 2:1 또는 3:1 복합체, 이의 제법 및 최면제로서의 이의 용도 | |
CN103505737B (zh) | 一种多烯紫杉醇/β-环糊精包合物的制备方法 | |
Hong et al. | Synthesis and anti-myocarditis activity in a multifunctional lanthanide microporous metal-organic framework with 1D helical chain building units | |
KR101557413B1 (ko) | 알파-나프토플라본의 수용성 개선용 조성물 및 그 방법 | |
CN106727363B (zh) | 核苷氨基磷酸酯类前药的冻干形式的药物组合物 | |
WO2023028003A1 (en) | Treatment of covid-19 | |
Chadha et al. | Inclusion parameters of pioglitazone hydrochloride and glipizide with β-cyclodextrin and its methyl derivative: calorimetric and | |
CN102989003A (zh) | 口服萘普生-环糊精包合物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140318 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140617 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140805 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141104 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141111 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150421 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150520 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5752710 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |